Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma.

ABSTRACT:

Introduction

Cabozantinib has been approved by the European Medicine Agency (EMA) for hepatocellular carcinoma (HCC) previously treated with sorafenib. Cabozantinib is also being tested in combination with immune checkpoint inhibitors in the frontline setting. Real-life clinical data of cabozantinib for HCC are still lacking. Moreover, the prognostic factors for HCC treated with cabozantinib have not been investigated.

Methods

We evaluated clinical data and outcome of HCC patients who received cabozantinib in the legal context of named patient use in Italy.

Results

Ninety-six patients from 15 centres received cabozantinib. All patients had preserved liver function (Child-Pugh A), mostly with an advanced HCC (77.1%) in a third-line setting (75.0%). The prevalence of pe

SUBMITTER: Tovoli F 

PROVIDER: S-EPMC8339460 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature